Journal article
G. Lorenzo, D. Hormuth, Angela M. Jarrett, E. Lima, Shashank Subramanian, G. Biros, J. Oden, T. Hughes, T. Yankeelov
ArXiv, 2021
ArXiv, 2021
Semantic Scholar
ArXiv
DBLP
Cite
Cite
APA
Click to copy
Lorenzo, G., Hormuth, D., Jarrett, A. M., Lima, E., Subramanian, S., Biros, G., … Yankeelov, T. (2021). Quantitative in vivo imaging to enable tumor forecasting and treatment optimization. ArXiv.
Chicago/Turabian
Click to copy
Lorenzo, G., D. Hormuth, Angela M. Jarrett, E. Lima, Shashank Subramanian, G. Biros, J. Oden, T. Hughes, and T. Yankeelov. “Quantitative in Vivo Imaging to Enable Tumor Forecasting and Treatment Optimization.” ArXiv (2021).
MLA
Click to copy
Lorenzo, G., et al. “Quantitative in Vivo Imaging to Enable Tumor Forecasting and Treatment Optimization.” ArXiv, 2021.
BibTeX Click to copy
@article{g2021a,
title = {Quantitative in vivo imaging to enable tumor forecasting and treatment optimization},
year = {2021},
journal = {ArXiv},
author = {Lorenzo, G. and Hormuth, D. and Jarrett, Angela M. and Lima, E. and Subramanian, Shashank and Biros, G. and Oden, J. and Hughes, T. and Yankeelov, T.}
}
Abstract
Current clinical decision-making in oncology relies on averages of large patient populations to both assess tumor status and treatment outcomes. However, cancers exhibit an inherent evolving heterogeneity that requires an individual approach based on rigorous and precise predictions of cancer growth and treatment response. To this end, we advocate the use of quantitative in vivo imaging data to calibrate mathematical models for the personalized forecasting of tumor development. In this chapter, we summarize the main data types available from both common and emerging in vivo medical imaging technologies, and how these data can be used to obtain patient-specific parameters for common mathematical models of cancer. We then outline computational methods designed to solve these models, thereby enabling their use for producing personalized tumor forecasts in silico, which, ultimately, can be used to not only predict response, but also optimize treatment. Finally, we discuss the main barriers to making the above paradigm a clinical reality.
